| Literature DB >> 33623038 |
Minh-Phuong Huynh-Le1,2, Chun Chieh Fan2, Roshan Karunamuni1,2, Wesley K Thompson3,4, Maria Elena Martinez5, Rosalind A Eeles6,7, Zsofia Kote-Jarai6, Kenneth Muir8,9, Johanna Schleutker10,11, Nora Pashayan12,13,14, Jyotsna Batra15,16, Henrik Grönberg17, David E Neal18,19,20, Jenny L Donovan21, Freddie C Hamdy22,23, Richard M Martin21,24,25, Sune F Nielsen26,27, Børge G Nordestgaard26,27, Fredrik Wiklund17, Catherine M Tangen28, Graham G Giles29,30,31, Alicja Wolk32,33, Demetrius Albanes34, Ruth C Travis35, William J Blot36,37, Wei Zheng36, Maureen Sanderson38, Janet L Stanford39,40, Lorelei A Mucci41, Catharine M L West42, Adam S Kibel43, Olivier Cussenot44,45, Sonja I Berndt34, Stella Koutros34, Karina Dalsgaard Sørensen46,47, Cezary Cybulski48, Eli Marie Grindedal49, Florence Menegaux50,51, Kay-Tee Khaw52, Jong Y Park53, Sue A Ingles54, Christiane Maier55, Robert J Hamilton56,57, Stephen N Thibodeau58, Barry S Rosenstein59,60, Yong-Jie Lu61, Stephen Watya62, Ana Vega63,64,65, Manolis Kogevinas66,67,68, Kathryn L Penney69, Chad Huff70, Manuel R Teixeira71,72, Luc Multigner73, Robin J Leach74, Lisa Cannon-Albright75,76, Hermann Brenner77,78,79, Esther M John80, Radka Kaneva81, Christopher J Logothetis82, Susan L Neuhausen83, Kim De Ruyck84, Hardev Pandha85, Azad Razack86, Lisa F Newcomb39,87, Jay H Fowke88,89, Marija Gamulin90, Nawaid Usmani91,92, Frank Claessens93, Manuela Gago-Dominguez94,95, Paul A Townsend96, William S Bush97, Monique J Roobol98, Marie-Élise Parent99,100, Jennifer J Hu101, Ian G Mills22, Ole A Andreassen102, Anders M Dale2,103, Tyler M Seibert104,105,106,107.
Abstract
Genetic models for cancer have been evaluated using almost exclusively European data, which could exacerbate health disparities. A polygenic hazard score (PHS1) is associated with age at prostate cancer diagnosis and improves screening accuracy in Europeans. Here, we evaluate performance of PHS2 (PHS1, adapted for OncoArray) in a multi-ethnic dataset of 80,491 men (49,916 cases, 30,575 controls). PHS2 is associated with age at diagnosis of any and aggressive (Gleason score ≥ 7, stage T3-T4, PSA ≥ 10 ng/mL, or nodal/distant metastasis) cancer and prostate-cancer-specific death. Associations with cancer are significant within European (n = 71,856), Asian (n = 2,382), and African (n = 6,253) genetic ancestries (p < 10-180). Comparing the 80th/20th PHS2 percentiles, hazard ratios for prostate cancer, aggressive cancer, and prostate-cancer-specific death are 5.32, 5.88, and 5.68, respectively. Within European, Asian, and African ancestries, hazard ratios for prostate cancer are: 5.54, 4.49, and 2.54, respectively. PHS2 risk-stratifies men for any, aggressive, and fatal prostate cancer in a multi-ethnic dataset.Entities:
Mesh：
Year: 2021 PMID： 33623038 PMCID： PMC7902617 DOI： 10.1038/s41467-021-21287-0
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919